CSI Market
Sign In | Register

Evofem Biosciences Inc (EVFM) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access EVFM quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Evofem Biosciences Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income0.39
Depreciation & amortization0.02
Amortization of Other Assets0.50
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.26
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.02
Share-based Compensation0.17
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gain Loss On Issuance Of Convertible Preferred Stock-
Liabilities Fair Value Adjustment-
Increase Decrease In Operating Lease Liabilities-
Loss On Issuance Of Warrants-
Loss On Issuance Of Financial Instruments-
Lease Cost-
Loss On Issuance Of Financial Instruments Net Of Modification Expense-
Fair Value Option Changes In Fair Value Gain Loss-
Loss On Issuance Of Purchase Rights-
Gain Loss On Issuance Of Financial Instruments-
Change In Fair Value Of Financial Instruments0.36
Financial Instrument Modification Expense-
Interest Expense2.37
Gain Loss On Accounts Payable Settlements-5.64
Increase Decrease In Operating Lease Liability-0.11
Income taxes0.00
Gain (Loss) on Sale of Derivatives0.00
Accounts Receivable-3.56
Increase (Decrease) in Accounts Payable0.18
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities4.47
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.36
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.26
Discontinued operations0.00
Net Cash flow from Operating Activities-1.99
Investing Activities
Capital Expenditures-0.06
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.06
Financing Activities
Short-term debt Net-0.52
Other borrowing transactions0.00
Long-term debt - borrowings2.43
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.01
Proceeds From Notes Payable And Bank Loan-
Early Repayment Of Debt-
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Short Swing Profit Disgorgement-
Proceeds From Issuance Of Common Stock Net Of Commissions-
Deferred Offering Costs Included In Accounts Payable And Accrued Expense-
Receivable From Issuance Of Common Stock-
Capital Expenditures Incurred But Not Yet Paid-
Conversion Of Stock Amount Converted-
Temporary Equity Value Exchange Of Convertible Securities-
Proceeds From Issuance Of Common Stock Stock Purchase Agreement-
Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs-
Proceeds From Issuance Of Common Stock The Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.89
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-2.05
Total Cash Flow-0.16
4 historic quarters locked

Sign in to unlock the full Evofem Biosciences Inc cash flow history.

Sign In Create Free Account

About Evofem Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: March 11, 2026
  • Source: form10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-009686

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License